Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For First Quarter Earnings Conference Call Tuesday April 17, 2001 Live At 4:30 P.M. Eastern Time

Apr 03, 2001, 01:00 ET from Arena Pharmaceuticals, Inc.

    SAN DIEGO, April 3 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
 (Nasdaq: ARNA) today announced that it will host both a telephone and internet
 first quarter conference call on Tuesday, April 17, 2001 at 4:30 p.m. Eastern
 Time (1:30 p.m. San Diego Time).
     Jack Lief, president and chief executive officer, and Joseph Mooney, chief
 financial officer, will discuss the first quarter results, the progress of
 Arena's collaborations, Project Genesis and other topics.  A Question and
 Answer session will follow the presentation.  To access by telephone, dial in
 toll free at (888) 273-9885 and specify that you would like to join the "First
 Quarter Earnings Conference Call."  To access the call via the Internet, go to
 www.arenapharm.com and click on "Investor Relations."  Then, click on
 "Calendar of Events."  The conference call will be listed at the top of the
 page.  Click on the "Live Webcast" link.  Then, follow the links and
 instructions provided.  Listening to the conference call on the Internet will
 require speakers and RealPlayer.
 
     Arena's CART Technology allows for the direct identification of modulators
 of G protein-coupled receptors in a ligand-independent manner, making the
 technology particularly useful with respect to orphan GPCRs which are
 estimated to comprise approximately 2% of the human genome.  Such ligand-
 independent screening is made possible by genetic alteration of these
 receptors, using routinely applicable and proprietary genetic cassettes.
 Arena has recently initiated "Project Genesis," an internal program aimed at
 obtaining all of the human GPCRs, identifying the location of these receptors
 within the human body for purposes of understanding the function of such
 receptors, and screening each GPCR to identify receptor modulators that form
 the basis of drug candidates.  Arena's CART Technology, in conjunction with
 Arena's recent acquisition of Bunsen Rush Laboratories, Inc. and the recently
 announced genomics database subscription agreement with Celera Genomics, is
 intended to facilitate completion of Project Genesis within the next three to
 five years.
 
     Certain statements in this press release are forward-looking statements
 that involve a number of risks and uncertainties, and actual events or results
 may differ materially from Arena's and BRL Screening, Inc.'s expectations.
 Statements that are not historical facts, including statements which are
 preceded by, followed by, or that include the words "intends," "will,"
 "plans," "expects," "anticipates," "estimates," "aim" and "believes" or
 similar statements are forward-looking statements.  Important factors that
 could cause actual results to differ materially from those stated or implied
 by our forward looking statements due to risks and uncertainties associated
 with Arena's and BRL's business include, but are not limited to, the
 following: the ability to complete Project Genesis, if at all, within a
 reasonable time period; future quarterly or annual financial results; the
 timing, success and cost of preclinical research, out-licensing endeavors and
 clinical studies, and receipt of additional milestone payments, if any, from
 collaborators.  Additional risk factors that could cause actual results to
 differ materially from those in our forward looking statements are disclosed
 in Arena's SEC reports, including but not limited to Arena's Form S-1, most
 recent quarterly report on Form 10-Q, and most recent annual report on Form
 10-K.  These forward-looking statements represent Arena's judgment as of the
 date of this release.  Arena and BRL disclaim, however, any intent or
 obligation to update these forward-looking statements.
     "Arena Pharmaceuticals" is a registered U.S. trademark of the company.
 "Arena" and "CART" are trademarks of the company.  Arena's headquarters are
 located at 6166 Nancy Ridge Drive, San Diego, CA 92121.  Arena's telephone
 number is (858) 453-7200.  On the Internet, please refer to Arena's website:
 http://www.arenapharm.com or BRL Screening's website:
 http://www.brlscreening.com for further information regarding CART Technology
 and the Melanophore Technology.
 
     For further information, contact:  Jack Lief, President & CEO: Extension
 223, or Joseph Mooney, CFO: Extension 508.
 
 

SOURCE Arena Pharmaceuticals, Inc.
    SAN DIEGO, April 3 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
 (Nasdaq: ARNA) today announced that it will host both a telephone and internet
 first quarter conference call on Tuesday, April 17, 2001 at 4:30 p.m. Eastern
 Time (1:30 p.m. San Diego Time).
     Jack Lief, president and chief executive officer, and Joseph Mooney, chief
 financial officer, will discuss the first quarter results, the progress of
 Arena's collaborations, Project Genesis and other topics.  A Question and
 Answer session will follow the presentation.  To access by telephone, dial in
 toll free at (888) 273-9885 and specify that you would like to join the "First
 Quarter Earnings Conference Call."  To access the call via the Internet, go to
 www.arenapharm.com and click on "Investor Relations."  Then, click on
 "Calendar of Events."  The conference call will be listed at the top of the
 page.  Click on the "Live Webcast" link.  Then, follow the links and
 instructions provided.  Listening to the conference call on the Internet will
 require speakers and RealPlayer.
 
     Arena's CART Technology allows for the direct identification of modulators
 of G protein-coupled receptors in a ligand-independent manner, making the
 technology particularly useful with respect to orphan GPCRs which are
 estimated to comprise approximately 2% of the human genome.  Such ligand-
 independent screening is made possible by genetic alteration of these
 receptors, using routinely applicable and proprietary genetic cassettes.
 Arena has recently initiated "Project Genesis," an internal program aimed at
 obtaining all of the human GPCRs, identifying the location of these receptors
 within the human body for purposes of understanding the function of such
 receptors, and screening each GPCR to identify receptor modulators that form
 the basis of drug candidates.  Arena's CART Technology, in conjunction with
 Arena's recent acquisition of Bunsen Rush Laboratories, Inc. and the recently
 announced genomics database subscription agreement with Celera Genomics, is
 intended to facilitate completion of Project Genesis within the next three to
 five years.
 
     Certain statements in this press release are forward-looking statements
 that involve a number of risks and uncertainties, and actual events or results
 may differ materially from Arena's and BRL Screening, Inc.'s expectations.
 Statements that are not historical facts, including statements which are
 preceded by, followed by, or that include the words "intends," "will,"
 "plans," "expects," "anticipates," "estimates," "aim" and "believes" or
 similar statements are forward-looking statements.  Important factors that
 could cause actual results to differ materially from those stated or implied
 by our forward looking statements due to risks and uncertainties associated
 with Arena's and BRL's business include, but are not limited to, the
 following: the ability to complete Project Genesis, if at all, within a
 reasonable time period; future quarterly or annual financial results; the
 timing, success and cost of preclinical research, out-licensing endeavors and
 clinical studies, and receipt of additional milestone payments, if any, from
 collaborators.  Additional risk factors that could cause actual results to
 differ materially from those in our forward looking statements are disclosed
 in Arena's SEC reports, including but not limited to Arena's Form S-1, most
 recent quarterly report on Form 10-Q, and most recent annual report on Form
 10-K.  These forward-looking statements represent Arena's judgment as of the
 date of this release.  Arena and BRL disclaim, however, any intent or
 obligation to update these forward-looking statements.
     "Arena Pharmaceuticals" is a registered U.S. trademark of the company.
 "Arena" and "CART" are trademarks of the company.  Arena's headquarters are
 located at 6166 Nancy Ridge Drive, San Diego, CA 92121.  Arena's telephone
 number is (858) 453-7200.  On the Internet, please refer to Arena's website:
 http://www.arenapharm.com or BRL Screening's website:
 http://www.brlscreening.com for further information regarding CART Technology
 and the Melanophore Technology.
 
     For further information, contact:  Jack Lief, President & CEO: Extension
 223, or Joseph Mooney, CFO: Extension 508.
 
 SOURCE  Arena Pharmaceuticals, Inc.